Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Candel Therapeutics (CADL) just unveiled an update.
Candel Therapeutics, Inc. has revealed promising interim results from a phase 2 trial of CAN-2409 for treating non-metastatic pancreatic cancer, showing notably improved survival rates compared to the control group. Patients treated with CAN-2409 experienced a median overall survival of nearly 29 months, a stark contrast to the 12.5 months in the control group. Moreover, the treatment induced a significant immune response and maintained a favorable safety profile, bolstering hope for its potential as a viable therapeutic option.
See more data about CADL stock on TipRanks’ Stock Analysis page.